Intravenous vs. Oral Proton-Pump Inhibitors for Bleeding Peptic Ulcers

Results of a meta-analysis suggest equal effectiveness but require validation in a larger study.

The use of proton-pump inhibitors (PPIs) has been shown to decrease rebleeding in patients with bleeding peptic ulcers (PUB) and high-risk stigmata for rebleeding. In most studies, patients have received intravenous (IV) PPIs for 3 days after endoscopic therapy. Few studies have compared oral with IV therapy in this setting.

To investigate this issue, researchers conducted a systematic review and meta-analysis of available studies. They identified six randomized, prospective studies in which clinical outcomes were compared in 615 patients with PUB (mean age, 60; 71% men) who received oral or IV PPIs.

The pooled data showed no difference in rebleeding, blood transfusions, surgery, or all-cause mortality. Length of stay was shorter for patients…

Reviewing Author

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

David J. Bjorkman, MD, MSPH (HSA), SM (Epid.)

Disclosures

Nothing to disclose

Intravenous vs. Oral Proton-Pump Inhibitors for Bleeding Peptic Ulcers

Topics

Reviewing Author